Occurrence of adverse events associated with the initiation of methotrexate and biologics for the treatment of psoriasis in routine clinical practice
Background: Limited information exists on the risk of adverse events (AEs) attributed to methotrexate (MTX) and biologics for the treatment of psoriasis/psoriatic arthritis (PsA/PsO) in heterogeneous clinical practice and beyond the duration of clinical trials. Methods: An observational study of 629...
Saved in:
Main Authors: | Faizan Mazhar (Author), Åsa Krantz (Author), Lovisa Schalin (Author), Josefin Lysell (Author), Juan Jesus Carrero (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Psoriasis/Psoriatic Arthritis Patients' Long-term Treatment Patterns and Adherence to Systemic Treatments Monitoring Recommendations
by: Åsa Krantz, et al.
Published: (2023) -
Assessment and monitoring of biologic drug adverse events in patients with psoriasis
by: Hanley T, et al.
Published: (2016) -
Systemic treatment of psoriasis: from methotrexate to biologics
by: Olga Yu. Olisova, et al.
Published: (2020) -
Cardiovascular adverse event reporting in psoriasis and psoriatic arthritis biological therapy clinical trials
by: Sreejan Saha, BA, et al.
Published: (2024) -
Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab
by: Jochen H. Hoffmann, et al.
Published: (2017)